AAT Antibody (9): sc-130299

AAT Antibody (9) is a mouse monoclonal IgG1 antibody that detects α 1-antitrypsin (AAT) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). AAT is a crucial hepatic acute phase protein composed of 394 amino acids, primarily functioning to inhibit Neutrophil Elastase, thereby playing a vital role in protecting lung tissue from damage and preventing the development of pulmonary emphysema, a debilitating and irreversible lung disease characterized by the loss of elasticity. AAT is predominantly expressed in the liver and cultured hepatoma cells, with lower levels found in macrophages, highlighting its importance in the hepatic response to inflammation. AAT is known for its high polymorphism and glycosylation, which contribute to its diverse isoelectric-focusing patterns observed in various genetic variants. The gene encoding AAT is located on human chromosome 14, adjacent to a related serine protease inhibitor gene that encodes corticosteroid-binding globulin, indicating a complex regulatory network for protease inhibition. Notably, the oxidation of the methionine 358 residue in AAT′s active site significantly impairs its ability to inhibit elastase, underscoring the importance of post-translational modifications in maintaining functional integrity. AAT deficiency is linked to a 20-30 fold increased risk of developing early-onset pulmonary emphysema, making the study of AAT and its interactions critical for understanding and potentially mitigating lung diseases. Anti-AAT antibody (9) is an essential tool for researchers investigating the role of AAT in pulmonary health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

AAT Antibody (9) References:

1. Basic and clinical aspects of the alpha1-antitrypsin.  |  Talamo, RC. 1975. Pediatrics. 56: 91-9. PMID: 1099521
2. Alpha1-antitrypsin inhibits angiogenesis and tumor growth.  |  Huang, H., et al. 2004. Int J Cancer. 112: 1042-8. PMID: 15316942
3. Lung disease associated with alpha1-antitrypsin deficiency.  |  Tuder, RM., et al. 2010. Proc Am Thorac Soc. 7: 381-6. PMID: 21030517
4. Appropriateness of newborn screening for α1-antitrypsin deficiency.  |  Teckman, J., et al. 2014. J Pediatr Gastroenterol Nutr. 58: 199-203. PMID: 24121147
5. α₁-Antitrypsin level and pheno/genotypes.  |  Ferrarotti, I., et al. 2013. Chest. 144: 1732-1733. PMID: 24189872
6. Augmentation treatment for α1 antitrypsin deficiency.  |  Crystal, RG. 2015. Lancet. 386: 318-20. PMID: 26026937
7. Human placental proteomics and exon variant studies link AAT/SERPINA1 with spontaneous preterm birth.  |  Tiensuu, H., et al. 2022. BMC Med. 20: 141. PMID: 35477570
8. Fazirsiran shows promise for liver disease in AAT.  |  Ray, K. 2022. Nat Rev Gastroenterol Hepatol. 19: 556. PMID: 35879355
9. Local Alpha1-Antitrypsin Accelerates the Healing of Tympanic Membrane Perforation in Mice.  |  El-Saied, S., et al. 2024. Laryngoscope. 134: 3802-3806. PMID: 38651563
10. Inhaled alpha-1 antitrypsin (AAT) restores lower respiratory tract protease-antiprotease homoeostasis and reduces inflammation in AAT-deficient individuals: a randomised phase 2 study.  |  Brantly, M., et al. 2025. ERJ Open Res. 11: PMID: 39811545

The preferred AAT antibody is AAT Antibody (B9): sc-59438.